Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

A Modular, Phase II, Open-Label, Multicentre Study to Assess the Preliminary Efficacy and Safety of RXC004, in Patients With Advanced Solid Tumours That Have Progressed Following Therapy With Current Standard of Care

NCT04907851 is registered in ClinicalTrials.gov with Redx Pharma Ltd as lead sponsor.

NCT NCT04907851
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT04907851 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
A Modular, Phase II, Open-Label, Multicentre Study to Assess the Preliminary Efficacy and Safety of RXC004, in Patients With Advanced Solid Tumours That Have Progressed Following Therapy With Current Standard of Care
Lead sponsor
Redx Pharma Ltd
Phase
Phase 2
Overall status
Completed
Start date
December 10, 2021
Completion date
November 30, 2023
Enrollment
45 (actual)
Sites
13

Conditions

As the registry lists them; a condition with its own page is linked.

advanced solid tumours